ArticleInternational journal of physiology, pathophysiology and pharmacology2018
Does β-caryophyllene protect against renal dysfunction following ischemia-reperfusion injury in the rat?
Article in International journal of physiology, pathophysiology and pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 7 citations in OpenAlex.
- Investigation of the protective effect of beta caryophyllene against indomethacin-induced gastric ulcer in rats: in vivo and in vitro study.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- β-Caryophyllene, A Natural Dietary CB2 Receptor Selective Cannabinoid can be a Candidate to Target the Trinity of Infection, Immunity, and Inflammation in COVID-19.Frontiers in pharmacology · 2021Article
- Therapeutic Potential of β-Caryophyllene: A Dietary Cannabinoid in Diabetes and Associated Complications.Nutrients · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRenal ischemia-reperfusion injury (IRI) causes renal functional alterations which may lead to permanent renal impairment. β-caryophyllene (BCP), a natural bicyclic sesquiterpene, is an important constituent of many edible plants including spices. It is an FDA-approved food additive which possesses potent anti-inflammatory and antioxidant activities and has been shown to protect against chemotherapeutics-induced organ toxicities and against ischemic injuries to heart, liver and brain. Oxidative stress and inflammation is a main accompaniment of renal dysfunction, however, the effect of BCP on IRI-induced renal dysfunction has not been investigated yet and therefore the aim of this study was to investigate the effect of BCP on IRI-induced renal dysfunction.
methodsWistar rats underwent left renal warm ischemia for 40 minutes. G-BCP (n=13) received oral BCP (50 mg/kg/day) dissolved in a vehicle starting 7 days prior to IRI and continued 7 days thereafter when the renal functions of both kidneys and the markers of oxidative stress and pro-inflammatory cytokines were measured. G-Vx (n=13) underwent similar protocol but received vehicle only.
resultsIRI affected hemodynamic (renal blood flow and glomerular filtration rate) and tubular (urine volume, total and fractional urinary sodium excretion) parameters in the left ischemic kidney in G-Vx. Though, BCP did not affect any of these alterations in the ischemic kidney (P>0.05 for all). However, it attenuated the alterations in malondialdehyde (MDA) and glutathione (GSH) in the left ischemic kidney in G-BCP compared to G-Vx (9.3±2.1 vs. 4.8±1.0, P=0.047 and 18.1±2.5 vs. 13.6±1.7, P=0.09, respectively).
conclusionOur study results demonstrate that BCP attenuated the alterations in some of the oxidative stress markers. However, these were not translated in to the protective effects on the haemodynamic and tubular glomerular functions when measured seven days post-IRI. This suggests that BCP has a weak reno-protective effect under ischemic conditions.
Indexed as
Identifiers
30697363PMC6334221W2989955047What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.